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 Patient: Female, 51
 Final Diagnosis: Fecal incontinence
 Symptoms: Constipation • fecal incontinence
 Medication: —
 Clinical Procedure: Sacral nerve stimulator
 Specialty: Gastroenterology and Hepatology
 Objective: Rare co-existance of disease or pathology
 Background: Fecal incontinence and constipation are common gastrointestinal complaints, but rarely occur concurrently. 
Management of these seemingly paradoxical processes is challenging, as treatment of one symptom may ex-
acerbate the other.
 Case Report: A 51-year-old female with lifelong neurogenic bladder secondary to spina bifida occulta presented with pro-
gressive symptoms of daily urge fecal incontinence as well as hard bowel movements associated with strain-
ing and a sensation of incomplete evacuation requiring manual disimpaction. Pelvic floor testing showed poor 
ability to squeeze the anal sphincter, which indicated sphincter weakness as a major contributor to her fecal 
incontinence symptoms. Additionally, on defecography she was unable to widen her posterior anorectal angle 
or relax the anal sphincter during defecation consistent with dyssynergic defecation. A sacral nerve stimula-
tor was placed for management of her fecal incontinence. Interestingly, her constipation also dramatically im-
proved with sacral neuromodulation.
 Conclusions: This unique case highlights the emerging role of sacral nerve stimulation in the treatment of complex pelvic 
floor dysfunction with improvement in symptoms beyond fecal incontinence in a patient with dyssynergic-type 
constipation.
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Background
Fecal incontinence (FI), the unintentional loss of solid or liq-
uid stool, can be further classified as urge, which occurs de-
spite active efforts to retain stool or passively occurring with 
little or no forewarning [1]. Additionally, some patients may 
complain of fecal seepage, which is defined as leakage follow-
ing a bowel movement. The internal anal sphincter provides 
much of the involuntary (resting) tone, while the external anal 
sphincter (EAS) and puborectalis complex provide the majority 
of the voluntary squeeze tone. Management initially involves 
use of medications to improve stool consistency and Kegel ex-
ercises. Patients who do not respond may further benefit from 
biofeedback, which is a minimally invasive therapy that pro-
vides visual feedback aimed at re-education and strengthen-
ing of pelvic floor muscles [2]. Constipation is usually charac-
terized as fewer than three weekly bowel movements, passage 
of lumpy or hard stools, sensation of incomplete evacuation 
and/or anorectal blockage, straining excessively, or manu-
al maneuvers to facilitate defecation. Approximately 23% of 
patients with constipation have dyssynergic defecation (DD), 
which is defined as inadequate relaxation of the anal sphinc-
ters and pelvic floor during defecation [3]. Treatment typical-
ly involves use of biofeedback targeted at retraining the pel-
vic floor to relax and is effective in 72% of patient completing 
therapy [4–7]. FI and DD patients who are refractory to medi-
cations and pelvic floor biofeedback pose a significant dilem-
ma to practitioners, but a promising emerging therapy, sacral 
neuromodulation (SNS), has shown significant benefit in pa-
tients with FI and may offer hope for patients with DD.
Case Report
A 51-year-old G1P1 Caucasian female with lifelong neurogen-
ic bladder secondary to spina bifida occulta was referred for 
symptoms of constipation and (FI). She averaged one Bristol 
Type 1–2 stool every 5 days requiring frequent manual disim-
paction. Additionally, she reported twice weekly episodes of ur-
gent fecal seepage, which required the use of daily continence 
pads. Her symptoms did not improve with the addition of psyl-
lium and bisacodyl suppositories. A defecography suggested 
atrophy of the puborectalis and poor squeeze with EAS muscle 
atrophy. Anorectal manometry (ARM) showed a normal resting 
pressure with no augmentation of squeeze pressure, consistent 
with weak EAS (Figure 1). During bearing down, fixed perine-
al descent was noted with the inability to widen the posterior 
anorectal angle and poor evacuation of contrast with strain-
ing, consistent with DD. With pushing, ARM similarly demon-
strated type IV DD, which is classified as inability to generate 
adequate propulsive forces along with absent or incomplete 
relaxation of the anal sphincter [8] (Figure 2). Reflex and sen-
sory testing indicated an intact rectoanal inhibitory reflex and 
rectal hypersensitivity. The patient failed management with 
home and conventional biofeedback therapy. Following a suc-
cessful trial of temporary SNS with improvement in FI symp-
toms by 75%, the patient had a permanent SNS placed. One 
year later, the patient reports sustained improvement in con-
stipation and FI symptoms.
Discussion
Spina bifida is a birth defect leading to incomplete closure of 
the backbone and membranes surrounding the spinal cord. 
Spina bifida occulta, a milder subtype affecting up to 20% of 
healthy individuals, can be associated with a tethered cord. 
This causes abnormal stretching of the spinal cord over time 
resulting in neurological symptoms like bowel or bladder dys-
function [9]. Initially, conservative treatment is recommended 
for FI and/or DD, including dietary advice, medications, and 
biofeedback. SNS is indicated for FI management when con-
servative therapy fails. This involves stimulation of the anterior 
ramus of S3 or S4, which is thought to provoke pelvic afferent 
and central pathways. This patient presented with overlapping 
complaints of constipation, fecal urgency, and seepage. Her 
constipation symptoms were consistent with an evacuation 
disorder, which was attributable to her inability to relax her 
puborectalis muscle during defecation. Non-relaxation of the 
puborectalis with pushing prevents opening of the anorectal 
angle because the puborectalis is the strap muscle which sup-
ports the rectum. The patient’s fecal urgency and seepage may 
have been related to a combination of findings noted on her 
defecography and ARM, including rectal hypersensitivity, exter-
nal anal sphincter weakness, and overflow related to her DD.
Up to 89% of FI patients who undergo permanent SNS follow-
ing a successful temporary trial will report long-term symp-
tom improvement [10]. There is no apparent correlation of re-
sponse to SNS with age, symptom duration, BMI, type of FI 
(passive, urge, seepage), or ARM findings; however, the great-
er the symptom improvement during the temporary trial, the 
more likely the patient is to maintain long-term benefits [11]. 
Prior to the temporary SNS trial, our patient kept a bowel dia-
ry, which was used to determine symptom improvement dur-
ing the temporary trial known as percutaneous nerve evalua-
tion (PNE). PNE involves an office procedure or operating room 
procedure where flexible leads are placed in the S3 or S4 fora-
men and connected to an externally controlled device and left 
in place for one to four weeks. Following the temporary trial, 
a permanent SNS that can be implanted underneath the skin 
may be offered to patients who have >50% improvement in FI.
A few case series of patients with FI have shown increased 
retrograde movement and contractility during defecation on 
colon scintigraphy and colonic manometry, which suggest a 
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possible role for SNS in the treatment of constipation [12,13]. 
Additionally, SNS has been shown to increase anterograde and 
high amplitude pressure sequences on colonic manometry in 
eight patients [14]. Unfortunately, SNS has not been shown 
to consistently benefit patients suffering from constipation in 
clinical trials [15]. Large trials looking at subsets of constipa-
tion, including slow-transit and DD, have not yet been done.
This unique case illustrates constipation symptom improve-
ment with SNS in a patient with the inability to adequately 
Figure 1.  Resting and squeeze: defecography 
and ARM showing complementary 
findings of normal sphincter integrity 
and resting tone, suggestive of intact 
internal anal sphincter function. 
Additionally, during voluntary squeeze 
there was inability to contract the 
sphincter or augment sphincter 
pressure suggestive of external anal 
sphincter weakness.
Rectum
Resting Squeeze
Resting Squeeze
Anal sphincer
Figure 2.  Bearing Down: no significant 
evacuation of contrast or opening of 
anorectal angle on defecography. On 
ARM, there was no increase in rectal 
pressure, nor was there relaxation of 
the anal sphincter as compared to 
resting.
Rectum
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relax her pelvis during defecation, who interestingly also suf-
fered from weakness of the sphincter during squeeze, which 
contributed to her FI.
Conclusions
This case illustrates the uncommon occurrence of overlapping 
DD and FI with paradoxical inadequate pelvic relaxation and 
sphincter weakness. While SNS is increasingly being used in 
patients with refractory FI, its role in treatment of refractory 
constipation is unclear. This case suggests that SNS may have 
benefit in the dyssynergic subtype of constipation. Further 
studies evaluating SNS in this specific subset of constipation 
sufferers are needed.
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